Literature DB >> 20537877

The relevance of animal models in multiple sclerosis research.

Aleksandar Denic1, Aaron J Johnson, Allan J Bieber, Arthur E Warrington, Moses Rodriguez, Istvan Pirko.   

Abstract

Multiple Sclerosis (MS) is a complex disease with an unknown etiology and no effective cure, despite decades of extensive research that led to the development of several partially effective treatments. Researchers have only limited access to early and immunologically active MS tissue samples, and the modification of experimental circumstances is much more restricted in human studies compared to studies in animal models. For these reasons, animal models are needed to clarify the underlying immune-pathological mechanisms and test novel therapeutic and reparative approaches. It is not possible for a single mouse model to capture and adequately incorporate all clinical, radiological, pathological and genetic features of MS. The three most commonly studied major categories of animal models of MS include: (1) the purely autoimmune experimental autoimmune/allergic encephalomyelitis (EAE); (2) the virally induced chronic demyelinating disease models, with the main model of Theiler's Murine Encephalomyelitis Virus (TMEV) infection and (3) toxin-induced models of demyelination, including the cuprizone model and focal demyelination induced by lyso-phosphatidyl choline (lyso-lecithine). EAE has been enormously helpful over the past several decades in our overall understanding of CNS inflammation, immune surveillance and immune-mediated tissue injury. Furthermore, EAE has directly led to the development of three approved medications for treatment in multiple sclerosis, glatiramer acetate, mitoxantrone and natalizumab. On the other hand, numerous therapeutical approaches that showed promising results in EAE turned out to be either ineffective or in some cases harmful in MS. The TMEV model features a chronic-progressive disease course that lasts for the entire lifespan in susceptible mice. Several features of MS, including the role and significance of axonal injury and repair, the partial independence of disability from demyelination, epitope spread from viral to myelin epitopes, the significance of remyelination has all been demonstrated in this model. TMEV based MS models also feature several MRI findings of the human disease. Toxin-induced demyelination models has been mainly used to study focal demyelination and remyelination. None of the three main animal models described in this review can be considered superior; rather, they are best viewed as complementary to one another. Despite their limitations, the rational utilization and application of these models to address specific research questions will remain one of the most useful tools in studies of human demyelinating diseases.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Year:  2011        PMID: 20537877      PMCID: PMC3858209          DOI: 10.1016/j.pathophys.2010.04.004

Source DB:  PubMed          Journal:  Pathophysiology        ISSN: 0928-4680


  66 in total

1.  Direct comparison of demyelinating disease induced by the Daniel's strain and BeAn strain of Theiler's murine encephalomyelitis virus.

Authors:  Laurie J Zoecklein; Kevin D Pavelko; Jeff Gamez; Louisa Papke; Dorian B McGavern; Daren R Ure; M Kariuki Njenga; Aaron J Johnson; Shunya Nakane; Moses Rodriguez
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

2.  Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis.

Authors:  Allan J Bieber; Daren R Ure; Moses Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2005-01       Impact factor: 3.685

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 4.  Epidemiologic contributions to multiple sclerosis: an overview.

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

5.  Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination.

Authors:  S A Shields; J M Gilson; W F Blakemore; R J Franklin
Journal:  Glia       Date:  1999-10       Impact factor: 7.452

6.  Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions.

Authors:  S L Hauser; A K Bhan; F Gilles; M Kemp; C Kerr; H L Weiner
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

7.  Demyelination induced by Theiler's virus: influence of the H-2 haplotype.

Authors:  M Rodriguez; C S David
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  Multiple sclerosis: pathogenesis and MR imaging features of T1 hypointensities in a [corrected] murine model.

Authors:  Istvan Pirko; Tifany K Nolan; Scott K Holland; Aaron J Johnson
Journal:  Radiology       Date:  2008-03       Impact factor: 11.105

9.  Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis.

Authors:  M Rodriguez; J L Leibowitz; P W Lampert
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

10.  ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS.

Authors:  T M Rivers; F F Schwentker
Journal:  J Exp Med       Date:  1935-04-30       Impact factor: 14.307

View more
  99 in total

Review 1.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 3.  Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption.

Authors:  Holly L Johnson; Fang Jin; Istvan Pirko; Aaron J Johnson
Journal:  J Neurovirol       Date:  2013-07-16       Impact factor: 2.643

4.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

5.  Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice.

Authors:  Emily G Baxi; Joseph DeBruin; Dominique M Tosi; Inna V Grishkan; Matthew D Smith; Leslie A Kirby; Hayley J Strasburger; Amanda N Fairchild; Peter A Calabresi; Anne R Gocke
Journal:  J Neurosci       Date:  2015-06-03       Impact factor: 6.167

6.  Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells.

Authors:  Agnieszka Rynda-Apple; Eduardo Huarte; Massimo Maddaloni; Gayle Callis; Jerod A Skyberg; David W Pascual
Journal:  Eur J Immunol       Date:  2010-12-29       Impact factor: 5.532

7.  Evaluation of a transgenic mouse model of multiple sclerosis with noninvasive methods.

Authors:  Mabel Enriquez-Algeciras; Di Ding; Tsung-Han Chou; Jianhua Wang; Kyle R Padgett; Vittorio Porciatti; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-14       Impact factor: 4.799

8.  Brain atrophy in picornavirus-infected FVB mice is dependent on the H-2Db class I molecule.

Authors:  April M Huseby Kelcher; Pascal A Atanga; Jeffrey D Gamez; Luz M Cumba Garcia; Stephanie J Teclaw; Kevin D Pavelko; Slobodan I Macura; Aaron J Johnson
Journal:  FASEB J       Date:  2017-02-10       Impact factor: 5.191

Review 9.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

10.  Functional Effects of Cuprizone-Induced Demyelination in the Presence of the mTOR-Inhibitor Rapamycin.

Authors:  Hana Yamate-Morgan; Kelli Lauderdale; Joshua Horeczko; Urja Merchant; Seema K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2019-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.